Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for
the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents
of this announcement.
HAO WEN HOLDINGS LIMITED
皓文控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8019)
ENTERING INTO A SUPPLYMENTARY CO-OPERATIVE
AGREEMENT IN RESPECT OF AN EXCLUSIVE RIGHT TO PRODUCE
AND SELL A MEDICAL PRODUCT
This announcement is made pursuant to Rule 17.10 of the GEM Listing Rules.
Everpride Pharmaceutical, a wholly-owned subsidiary of the Company, entered into a Co-operative Agreement
with Beijing Jia Hong Yu on 8 February 2002 with immediate effect for a term of 10 years. On 5 February 2012,
Everpride Pharmaceutical and Beijing Jia Hong Yu entered into a supplementary agreement to the Co-operative
Agreement.
This announcement is made pursuant to Rule 17.10 of the GEM Listing Rules.
Reference is made to the Company’s announcement dated 8 February 2002 (the “Announcement”) in relation to
entering into a Co-operative Agreement in respect of an exclusive right to produce and sell a new medical
product, namely Puli Capsule. Terms used herein shall have the same meanings as defined in the Announcement
unless defined otherwise.
BACKGROUND INFORMATION
Everpride Pharmaceutical entered into a Co-operative Agreement with Beijing Jia Hong Yu on 8 February 2002
with immediate effect for a term of 10 years. The Co-operative Agreement entitles Everpride Pharmaceutical to
have the exclusive right to produce and sell Puli Capule. Puli Capule is a medicine for the treatment of
osteoarthritis. The Co-operative Agreement will expire on 7 February 2012. The Board is pleased to announce
that on 5 February, 2012, Everpride Pharmaceutical entered into a supplementary agreement (the
“Supplementary Agreement”) to the Co-operative Agreement with Beijing Jia Hong Yu.
1
TERMS OF THE SUPPLEMENTARY AGREEMENT
Basically, Everpride Pharmaceutical can continue to have the exclusive right to produce and sell Puli Capule
(the “Exclusive Right”) after the expiry date of the Co-operative Agreement under the terms and clauses of the
Co-operative Agreement until the disposal of the Exclusive Right. The Exclusive Right is jointly owned by
Everpride Pharmaceutical and Beijing Jia Hong Yu and can only be disposed by mutual consent of Everpride
Pharmaceutical and Beijing Jia Hong Yu. The proceeds from disposal of the Exclusive Right will be equally
shared by Everpride Pharmaceutical and Beijing Jia Hong Yu.
REASONS FOR ENTERING INTO THE SUPPLEMENTARY AGREEMENT
In view of the performance of Puli Capsule in the past 10 years and the fierce competition in the pharmaceutical
industry in Mainland China, the Board considers the Supplementary Agreement is in the interest of the Group
and the Shareholders as a whole by enhancing the flexibility of the operation of the Group. The Group will
continue to engage in the manufacture and sale of medicines in Mainland China and trading of biodegradable
containers in Hong Kong. The Group will explore other business opportunities strengthen the profitability of the
Group.
GENERAL
At the date of this announcement, Everpride Pharmaceutical and Beijing Jia Hong Yu have no a fixed plan to
dispose the Exclusive Right. Further announcement will be made to inform the investors and
shareholders when Everpride Pharmaceutical and Beijing Jia Hong Yu have any plan to disposal the Exclusive
Right.
Save as disclosed in this announcement, there are no negotiations or agreements relating to intended
acquisitions or realisations which are discloseable under Chapters 19 and 20 of the GEM Listing Rules, neither
are the Board aware of any matter discloseable under the general obligation imposed by Rule 17.10 of the GEM
Listing Rules, which is or may be of a price-sensitive nature.
By Order of the Board
Hao Wen Holdings Limited
Leung King Fai
Executive Director
Hong Kong, 6 February 2012
This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars
given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock
Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors,
having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information
contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and
(2) there are no other matters the omission of which would make any statement herein or this announcement misleading.
2
As at the date hereof, the executive Directors are Mr. Zhao Borui, Mr. Hu Yangxiong, Mr. Lee Cheuk Yue, Ryan, Mr.
Chow Yik and Mr. Leung King Fai; the independent non-executive Directors are Ms. Yeung Mo Sheung, Ann, Mr. Lam
Kai Tai and Mr. Wong Ting Kon.
This announcement will remain on the GEM website at http://www.hkgem.com on the ‘‘Latest Company
Announcements” page for at least 7 days from the date of its posting and on the website of the Company at
http://www.tricor.com.hk/webservice/008019.
3